Magnesium supplementation improves metabolic profile of MONW men and women

Magnesium supplementation improves metabolic profile of MONW men and women

Life Extension Update

Tuesday, October 14, 2014. Metabolically obese, normal-weight (MONW) individuals are those who exhibit such metabolic syndrome components as fasting glucose levels of 100 milligrams per deciliter (mg/dL) or more, insulin resistance, elevated triglycerides, and/or high blood pressure in the absence of obesity. In a study described in the July 2014 issue of the Archives of Medical Research, Martha Rodríguez-Moran and Fernando Guerrero-Romero of the Mexican Social Security Institute's Biomedical Research Institute sought to determine the effects of magnesium supplementation in 47 MONW men and women with low serum magnesium levels. In a randomized double-blinded trial, participants were divided to receive a 5% magnesium chloride solution that provided 382 mg magnesium or a placebo solution daily for four months. Blood pressure and fasting plasma glucose, serum magnesium, triglycerides and insulin were measured before and after the treatment period.

Although no significant differences were observed between the groups before treatment, average systolic and diastolic blood pressure readings were lower at the end of four months among those who received magnesium, while those who received a placebo experienced an increase. While serum magnesium levels rose, fasting plasma glucose, insulin resistance and triglycerides were significantly lower in the magnesium-supplemented group compared to the placebo group by the end of the study.

The authors observe that "even among normal weight individuals, magnesium supplementation may be effective for the reduction of hyperglycemia, hypertriglyceridemia, insulin resistance, and blood pressure, features of the MONW phenotype."

"Our finding strongly suggests that irrespective of body weight, magnesium plays an important role in the regulation of metabolic disturbances and blood pressure," they conclude.

What's Hot
Supplementation with magnesium lowers CRP in prediabetics
brain volume  

An article published online on May 7, 2014 in the Archives of Medical Research reports the results of a double-blinded trial of subjects with prediabetes and low magnesium levels which found a benefit for magnesium supplementation in reducing C-reactive protein (CRP), a marker of inflammation.

The trial included 62 men and women between the ages of 18 to 65 years with newly diagnosed prediabetes who had magnesium levels below 0.74 micromoles per liter (mmol/L). Participants received an oral magnesium chloride solution containing 382 milligrams magnesium or a placebo daily for three months, and both groups received advice concerning physical activity and the components of a healthy diet. Plasma glucose, serum magnesium and high-sensitivity C-reactive protein (hsCRP) were measured before and after the treatment period.

By the end of the study, serum magnesium levels were higher, and fasting and two hour post-load glucose levels were lower among those who received magnesium in comparison with the placebo. While both groups experienced a decline in CRP, the decrease was significantly greater among those who received magnesium.

Authors Luis E. Simental-Mendía and colleagues note that magnesium deficiency has been proposed as an early factor in the activation of the inflammatory response. They recommend further clinical trials to establish whether magnesium deficiency plays a causative role in inflammation and to determine its mechanisms.

"Our results show that oral magnesium supplementation significantly decreases hsCRP levels in apparently healthy subjects with prediabetes and hypomagnesemia," the authors write. "Taking into account that elevated hsCRP is related to glucose metabolic disorders, our finding may have important implications in the policies focused in its prevention."

Life Extension Clinical Research Update

Participate in a Clinical Study:
Overweight and Mildly Elevated Blood Sugar
South Florida location

Study Objective:
Assess the effectiveness of nutritional supplements to improve blood sugar and blood vessel health over the course of 90 days.

To Qualify:

  • You must be between 25 and 65 years of age.
  • Have mildly elevated blood sugar with no previous diagnosis of diabetes.
  • Be overweight (BMI of 25 - 34.9).

Your Involvement:

  • You will make 5 visits over 90 days.
  • You will receive the nutritional supplement to be studied, blood tests, and blood vessel health evaluations.
  • Upon successful completion of the trial you will be compensated for time and travel up to $250 plus a $100 Life Extension® gift card.

Register For This Study
Or call 1-866-517-4536


Life Extension Magazine® October 2014 Issue now Online

Life Extension Magazine August 2014 Issue


Health Headlines

As we see it: Assembly Line Medicine, by William Faloon

Deadly Carbohydrates: The Lethal Sugar/Cancer Connection, by Stephanie Martinson

Unique Probiotic Targets Cardiovascular Disease, by Celine Thompson

Natural Extracts Lower Blood Pressure, by Brandon DeWitte

A Lifesaving Nutrient in Citrus Fruit, by Steven De Berg


Wellness Profile: Dr. Robert Huizenga, by Astrid Kessler

In the News

Journal abstracts


Health Concern

High blood pressure

brain volume  

Mainstream medicine has fallen fatally short of relieving high blood pressure. A major problem is that mainstream medicine's definition of what constitutes acceptable blood pressure levels is far too high. The medical establishment defines high blood pressure (hypertension) as over 139/89 mmHg. However, in 2006, researchers found that blood pressure levels ranging from 120-129 mmHg systolic/80-84 mmHg diastolic were associated with an 81% higher risk of cardiovascular disease compared to levels of less than 120/80 mmHg. Moreover, blood pressure levels of 130-139/85-89 mmHg were associated with a frightening 133% greater risk of cardiovascular disease compared to levels below 120/80 (Kshirsagar 2006). Worse yet, studies suggest that conventional physicians are unlikely to treat hypertension until levels exceed 160/90 mmHg, a level that dramatically increases the risk of disease and death (Hyman 2002).

Controlling blood pressure means radically reducing disease risk. Studies have estimated that reducing blood pressure by 10/5 mmHg, to no lower than 115/75, can reduce the risk of death due to stroke by 40% and the risk of death due to heart disease or other vascular causes by 30% (Lewington 2002). In individuals 40 to 70 years old, each 20/10 mmHg increment over 115/75 doubles the risk of heart attack, heart failure, stroke, or kidney disease (Lewington 2002; Chobanian 2003). Based on this and other data, Life Extension recognizes that for many individuals, a target blood pressure of 115/75 mmHg yields the best benefits (Chobanian 2003).

Read More
Latest Products
Mega Green Tea Extract

Advanced Anti-Adipocyte with Meratrim® and Integra-Lean® African Mango Irvingia, 60 vegetarian capsules

Item #01509
Add to Cart

Meratrim's® performance in clinical studies indicates it can safely deliver impressive results. In a key study, 30 adults with difficulty maintaining healthy body weight ingested 800 mg per day of Meratrim® while following a 2,000-calorie-per-day diet and were asked to walk just 30 minutes five days a week. A group of equal size was given a placebo. After just eight weeks, the Meratrim® group:

  • Lost 4.05 inches of harmful belly fat (2.0 times the placebo group).
  • Experienced a 2.05 drop in body mass index (BMI) (3.9 times over placebo).
  • Shed 11.4 pounds of total body weight (3.7 times over placebo).

And these improvements began to emerge after just 14 days.

This supplement should be taken in conjunction with a healthy diet and regular exercise program. Results may vary.
Integra-Lean® Irvingia is protected by U.S. Patent No. 7,537,790. Other patents pending.  IGOB-131® proprietary extract is a registered trademark of Gateway Health Alliances, Inc.  Meratrim® is a proprietary ingredient derived from natural plant extracts exclusively distributed by InterHealth N.I.

Prevagen® Extra Strength, 30 capsules

Item #01577
Add to Cart

Prevagen® is a first-of-its-kind brain health supplement and is the only product to contain the main ingredient "apoaequorin". First discovered in jellyfish, apoaequorin is now produced in a scientifically controlled process.

Prevagen® Extra Strength is designed to have twice the apoaequorin as regular strength Prevagen®. Apoaequorin is a protein which uniquely supports critical brain functions such as:

  • Memory
  • Overall mental clarity
  • Clearer thinking
  • Better concentration
  • Greater ability to focus

Prevagen® was tested in a large double-blind, placebo-controlled study using computers to assess brain performance. 218 adults over 40 years of age participated in the study. Prevagen signficantly improved learning and word recall.

Related Life Extension Magazine® Articles
Dr. Dennis Goodman: A Man On A Mission To Promote Magnesium Magnesium in Hypertension Prevention and Control